title: [Central precocious puberty is associated with a high prevalence of organic disease].
abstract: BACKGROUND
  The incidence of central precocious puberty (CPP) is lower in boys than in girls; however, the presence of organic disease is more common in boys.
  
  
  OBJECTIVE
  To investigate the percentage of CPP secondary to organic disease in boys and to analyze their clinical and biological characteristics at diagnosis, during follow-up, and at the end of therapy.
  
  
  METHODS
  Eight boys with a diagnosis of CPP treated with triptorelin every 28 days were included. Age, height in standard deviation (SD), body mass index (BMI) in SD, growth velocity in SD, bone age (Greulich and Pyle), predicted height (Bayle-Pinneau), and target height were analyzed. Testicular volume was measured (according to Prader standards) and peak lutein hormone (LH) values and testosterone levels were determined after gonadotropin-releasing hormone (GnRH) stimulus.
  
  
  RESULTS
  Seventy-five percent of the patients with CPP had organic disease. After treatment with triptorelin, growth reduction significantly decreased. In contrast, no changes were seen in the difference between bone age and chronological age, due to the slight difference found at diagnosis. Likewise, during treatment, there was no LH peak and testosterone levels were lower than 0.5 ng/ml in response to GnRH stimulus. No changes were observed in weight or BMI. Three patients reached an adult height similar to their genetic height and their predicted height, as estimated by the Bayle-Pinneau method.
  
  
  CONCLUSIONS
  1. Among boys with CPP we found a substantial number of patients with organic disease. 2. Adult height after treatment with triptorelin can reach the normal range. 3. Determination of testosterone levels can be useful in the follow-up of these children during treatment.
authors.affiliation: Servicio de Endocrinología, Departamento de Pediatría, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, España.
authors.forename: M J
authors.initials: MJ
authors.lastname: Martín Díaz
authors.forename: L
authors.initials: L
authors.lastname: Soriano Guillén
authors.forename: M T
authors.initials: MT
authors.lastname: Muñoz Calvo
authors.forename: J
authors.initials: J
authors.lastname: Pozo Román
authors.forename: J
authors.initials: J
authors.lastname: Argente Oliver
mesh_terms: D001827:Body Height; D001927:Brain Diseases / Q000175:diagnosis; D002648:Child; D002675:Child, Preschool; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis; D011629:Puberty, Precocious / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D012189:Retrospective Studies; D013739:Testosterone / Q000097:blood; D017329:Triptorelin Pamoate / Q000627:therapeutic use
chemical_list: D017329:Triptorelin Pamoate; D013739:Testosterone